

A systematic review on neuropsychological function in bipolar disorders type I and II and subthreshold bipolar disorders—something to think about

Sinead King,^{1*} James M Stone,^{1,2,3} Anthony Cleare,^{1,3} and Allan H Young^{1,3}

¹ Department of Psychological Medicine & Centre for Affective Disorders, King's College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK

² Centre for Neuroimaging Sciences, King's College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK

³ South London and Maudsley NHS Foundation Trust, United Kingdom

Neuropsychological dysfunction is a well-established finding in individuals with bipolar disorder type I (BP-I), even during euthymic periods; however, it is less clear whether this also pertains to bipolar disorder type II (BP-II) or those with subthreshold states (SBP; subthreshold bipolar disorder), such as bipolar not otherwise specified (BP-NOS). Herein, we compare the literature regarding neuropsychological performance in BP-II vs BP-I to determine the extent of relative impairment, and we present and review all related studies on cognition in SBP. After systematically searching PubMed, Medline, PsycINFO, and The Cochrane Library, we found 17 papers that comprise all the published studies relevant for this review. The areas that are consistently found to be impaired in BP are executive function, verbal memory, visual spatial working memory, and attention. More studies than not show no significant difference between BP-I and BP-II, particularly in euthymic samples. Preliminary evidence suggests that patients experiencing major depressive episodes who also meet criteria for SBP show similar profiles to BP-II; however, these results pertain only to a depressed sample. SBP were found to perform significantly better than both MDD and healthy controls in a euthymic sample. A consensus on mood state, patient selection, and neuropsychological testing needs to be agreed on for future research. Furthermore, no studies have used the most recent DSM-5 criteria for SBP; future studies should address this. Finally, the underlying bases of cognitive dysfunction in these diagnostic groups need to be further investigated. We suggest recommendations on all of the above current research challenges.

Received 15 December 2017; Accepted 2 October 2018

Key words: Cognition, Bipolar I, Bipolar II, Subthreshold Bipolar Disorders, executive function, attention.

Introduction

Bipolar disorders are a group of conditions that encompass pathological alterations in mood, activity, and biological rhythms. In addition to this, these disorders are associated with varying degrees of psychotic symptoms, loss of functioning, and neuropsychological impairments.¹ The last decade has witnessed a surge of interest particularly in the latter: the

neuropsychological correlates of this commonly occurring phenotype.

Neuropsychological dysfunction is a well-established finding in people with bipolar type I (BP-I), even in the euthymic state of the illness.^{2–5} Cognitive performance is an area of increasing interest in bipolar type II (BP-II), as recent studies have found that these patients also perform more poorly than healthy controls on neuropsychological tests.^{6–9} A previous review published by Sole et al⁸ suggested a possible subtle distinction in performance between BP-I and BP-II; however, they stated that more studies were needed in order to make any firm conclusions. Despite this, recent research has focused mainly on BP-I, partly due to researchers and clinicians attitudes toward BP-II, ie, recognizing the

* Address for correspondence: Sinead King, King's College London, Centre for Affective Disorders, Institute of Psychiatry, Psychology & Neuroscience, Department of Psychological Medicine, 103 Denmark Hill, London SE5 8AZ, UK.
(Email: sinead.king@kcl.ac.uk)

difficulty in differentiating BP-II from major depressive disorder (MDD) in those experiencing major depressive episodes (MDE). For example, 2 studies concluded that over 40% of bipolar disorders are misdiagnosed as MDD.^{10,11}

Even more challenging to diagnose accurately are subthreshold bipolar disorders (SBP), for example, bipolar not otherwise specified (BP-NOS) and those with mixed (ie, subthreshold hypomanic) features alongside their depressive episodes, which are most often misdiagnosed as MDD.

Current classifications have major limitations, and because of this, individuals are termed as “not otherwise specified” (BP-NOS). Similarly, the clinical entity termed MDD represents only the final, external manifestations of an enormously complex, multilevel, multifactorial process, and mood disorder research, particularly in the area of neuropsychological functioning, might benefit from stratifying these classifications into more homogenous dimensions of pathology. An alternative model is necessary to either complement or replace the traditional categorical approach. Recognizing the complexity of both uni/bipolarity and the limitations of current diagnostic systems should motivate researchers to work toward building alternative models for understanding these conditions.

Cognitive deficits in attention are part of the MDD current diagnostic criteria,¹² and deficits of attention and memory are often reported by patients suffering from this condition. However, there remains no agreement as to the nature and extent of dysfunction in depression, and the neuropsychological functioning of SBP, particularly in euthymic periods, has not yet been established.

Iverson et al¹³ found that a subgroup of mood disorder patients had frank cognitive impairments, but that the majority were broadly cognitively normal. A larger proportion of patients with bipolar disorder (41.9%) than patients with depression (27.1–28.6%) met criteria for cognitive impairment in this study. Iverson and colleagues concluded that future research should determine if this identified subgroup has neuroanatomical, neurophysiological, and/or neuroendocrine abnormalities. In addition, a meta-analysis revealed that euthymic MDD patients were characterized by significantly poorer cognitive functions; however the magnitude of observed deficits, with the exception of inhibitory control, were generally modest when late-onset cases were excluded.¹⁴ Late-onset cases demonstrated significantly more pronounced deficits in verbal memory, speed of information processing, and some executive functions. Bora et al¹⁴ concluded that more research was needed, particularly in remitted psychotic and melancholic MDD and in SBP disorders.

The aim of this review, therefore, is to provide an update on neuropsychological dysfunction in BP-II, since the earlier review by Sole et al⁸ and the meta-analysis by Bora et al¹⁴, with the aim of confirming whether BP-II patients do indeed differ from or whether they share a similar cognitive profile to that of BP-I. We will then focus on the neuropsychology of subthreshold bipolar disorders; we present and review all studies relating to neuropsychological function in this phenotype. Utilizing our findings from this review, we will discuss the plausibility for an alternative dimensional approach to bipolar disorders and whether the current taxonomy, which partitions what may essentially be better understood as a spectrum into discrete disorders, is the most valid approach. Last, and in keeping with this dimensional model, the underlying bases for cognitive dysfunction need to be investigated, and we suggest recommendations for future research.

Methods

A comprehensive search of PubMed, Medline, PsycINFO, and The Cochrane Library was carried out in order to conduct a systematic review of the available literature on neurocognitive function in hypomanic bipolar disorders; 17 studies met eligibility criteria (see Figure 1). Articles were excluded if they did not fit the eligibility criteria, ie, they examined constructs such as cognitive styles, extreme cognitions, and hyperthymic personalities. Eligibility criteria were (a) studies that included a comparison group [psychiatric or healthy control (HC) group], cross-sectional case-control studies or normative data for standardized tests; (b) published through to January 2017; and (c) adult patients (aged 18–65). Only English-language articles published through to January 2017 were included in the present review, using the search terms “bipolar,” “bipolar II,” “sub-syndromal bipolar,” “subthreshold bipolar,” “bipolar spectrum,” “other related bipolar,” “not otherwise specified,” “DSM-5 mixed episodes specifier,” “cyclothymia,” and “cyclothymic disorder,” cross-referenced with “cognition,” “cognitive function,” “cognitive impairment,” “neuropsychological,” “neurocognitive,” “attention,” “memory,” “verbal memory,” and “executive function.”

Search-Term Selection

The above cognitive domains were specifically chosen as search terms by the authors, as they have been found to show large effect sizes in bipolar disorder research, across the spectrum.¹⁵ See below for an outline of the current literature regarding each domain and the alterations involved, specifically in bipolar disorders.




FIGURE 1. Systematic search of cognition in BP II and SSBP.

Executive function

Currently, there is no consensus regarding the definition of executive function (EF), its components, and their neurobiological underpinnings. Despite these disagreements, an essential characteristic of EF is its capacity to coordinate cognition, behavior, and emotions and to direct an organism to establish goals. EF is a set of mental processes that helps connect past experience with present action. EF (ie, memory, planning, behavior) are all governed by the brain, particularly in the prefrontal cortex (PFC). The PFC and its related neural

circuitry are critically involved in executing many of the components underlying executive function: “The PFC is the most evolved brain region—and sub serves our highest-order cognitive abilities. However, it is also the brain region that is most sensitive to the detrimental effects of stress exposure” (p. 1).¹⁶ Executive function is also closely linked to emotional regulation,¹⁷ contributing to successful psychosocial functioning. According to Addis et al,¹⁸ even subtle changes in executive function may induce overgeneralization of the past or future events. See Table 1 for how executive function relates to bipolar disorders.

TABLE 1. Cognitive domains and alterations in mood disorders

Cognitive domain	Tasks	Description	Alterations in mood disorders
Executive Functions			
<u>Set shifting</u>	TMT-B	Joining dots and numbers interchangeably and as fast as possible	Euthymic Bipolar Disorders v Healthy Controls: Large effect sizes ($d \geq 0.8$) were noted for category fluency and mental manipulation
<u>Inhibition</u>	Wisconsin Card Sorting Test	Sorting cards according to shifting rules.	
• <i>Response inhibition</i>	Stop-Signal	Inhibit prepotent response when tone is heard	Moderate effect sizes were reported for indices of short and long delay verbal memory, response inhibition, and set-shifting
• <i>Interference control</i>	Stroop	Rapidly naming colors (e.g., "green") of ink in which color words (e.g., "red") are printed	
<u>Working memory</u>	Digit-Span Backward (DS-B)	Repeat a series of numbers in reverse order from which they are presented	Executive impairment in patients with bipolar disorder may reflect underlying dysfunction in the structural or functional neuroanatomy of the prefrontal cortex (PFC). Most studies that have investigated this relationship have done so in patients with mood symptoms however abnormalities have been found in the dorsolateral prefrontal cortex and the anterior cingulate cortex.
• <i>Verbal</i>	CANTAB SWM Task	Maintain spatial memory of already selected material	
• <i>Spatial</i>	Tower of London (ToL)	Move 3+ rings/balls to match a particular arrangement, while adhering to specific rules of how they can be moved	
<u>Planning</u>	F-A-S	Rapidly name words that begin with 'F' (or 'A' or 'S')	
<u>Category fluency</u>	Categories	Rapidly name words that belong to a category	
• <i>Phonemic</i>		Recalling a list of items from memory	Large effect sizes found for verbal learning, total learning trials 1–5 and moderate effect sizes for all other verbal learning tasks except forward digit span which showed small effect sizes.
• <i>Semantic</i>		Recalling a list of items from memory	
		Recalling items in order.	
Verbal memory	Rey Auditory Verbal Learning Test		
	California Verbal Learning Test (total learning trials 1–5, short delay (free) recall, and long delay (free) recall)		
	Forward Digit Span		
Attention	Trail Making Test A	Using paper and pen to connect a list of numbers in sequential order	Both MDD and bipolar disorders have elements of attention impairment as components of their diagnostic criteria, such as difficulty concentrating in major depression and behavioural evidence of distractibility in mania.
	Digit Symbol Substitution Test	A list of digits presented on paper and under each digit the subject should write down the corresponding symbol as fast as possible.	
Visual spatial working memory	Corsi Task	mimicking a researcher as he/she taps a sequence of up to nine identical spatially separated blocks.	This task places high demands on the capacity to monitor and manipulate cognitive representations and evidence suggests these cognitive processes are impaired in bipolar disorders. ¹⁹

Attention

Attention is a concept that includes a number of processes that work together and influence one another. These processes include working memory (which refers to the ability to keep a limited number of mental objects in awareness for a limited duration of time), vigilance (which is the capacity to identify a specific target among many other stimuli), freedom from distraction or interference, and the ability to split or to rapidly shift attention. Concentration is a term that refers to the ability to sustain attention over prolonged periods of time. There are many tests, with each of them assessing one of the previously mentioned processes. See Table 1 for how problems with attention relate to bipolar disorders.

Verbal learning and memory

Learning and memory occur over time and involve a number of different individual events, including

attention and concentration, encoding (learning), and retrieving (the memory). These processes are distinct from one another but are also interrelated and interdependent. Verbal memory is a broad term used to refer to the memory of language in various forms. This type of memory has commonly been linked to the left side of the brain. Particularly, it is generally associated with the medial temporal lobe on the left side. This is not the case in all individuals, though, and some individuals who use both sides of the brain to access this type of memory have demonstrably better verbal memories. See Table 1 for evidence of verbal learning and memory impairments in bipolar disorders.

Visual spatial working memory

Visual spatial working memory maintains spatial and visual information, thus ensuring the formation and manipulation of mental images. These processes have been linked to the right hemisphere. Visuospatial

TABLE 2. Quality assessment

	Quality rating	History of psychosis	Comorbidities	Use of antipsychotics
Bourne <i>et al</i> ²²	11	Not mentioned	No comorbidity controlled for	40% BP-I/ 34% BP-II
Kessler ²³	9	BDI 84/25% BDII	No comorbidity controlled for	64% of overall patient group but no mention of difference between groups
Aminoff <i>et al</i> ¹	14	Not mentioned	No comorbidity controlled for	AP not mentioned
Sparding ²⁴	12	73%v7%	No comorbidity controlled for	AP not mentioned
Lin <i>et al</i> ²⁵	12	Not mentioned	No comorbidity controlled for	AP not mentioned
Ha <i>et al</i> ²⁶	9	62.5%/11% psychosis symptoms,	Comorbidities not mentioned only comorbid ALD and SUD	Use of antipsychotics Not mentioned
Martinez-Aran <i>et al</i> ²⁷	10	No history of psychotic symptoms recorded	No comorbidity controlled for	No record of use of antipsychotics
Bruno <i>et al</i> ²⁸	9	No history of psychotic symptoms recorded	No comorbidity controlled for	No record of use of antipsychotics
Harkavy-Friedman <i>et al</i> ²⁹	9	Not recorded	Not recorded	Not recorded
Summers <i>et al</i> ³⁰	10	No mention of BDIVBDII History of psychosis	Co-morbid psychiatric condition excluded	No mention of use of antipsychotics.
Torrent <i>et al</i> ⁹	12	30% BDI V 5% BDII	No mention of comorbidity	19% BDI V 8 (BDII
Andersson <i>et al</i> ⁶	13	Not recorded	Comorbidities (anxiety, substance abuse, somatoform etc) included, no BPD	Not recorded
Dittmann <i>et al</i> ³¹	9	72% BP-I / 26% BP-II	Comorbidities likely to affect cognitive function excluded, no mention of current comorbidities.	51% BP-I / 24% BP-II
Savitz <i>et al</i> ³²	10	No mention of history of psychosis	No comorbidities especially alcohol dependence	24% BP-I/0% BPII
Simonsen <i>et al</i> ³³	11	81% BDI V 16% BDII	Psychiatric or medical (except neuro) comorbidities not mentioned	62% BP-I V 32% BP-II
Hsiao <i>et al</i> ³⁴	9	BP-I 73%/BP-II: 16% previous psychotic symptoms	All other Axis 1 diagnosis excluded	No record of Antipsychotics used in both populations. Unable to control for use of AP due to small sample size
Palsson ³⁵	11	52/67 BDI, 7/43 BDII	Anxiety and ADHD controlled for	22/67 BDI, 6/43 BDII,
Smith ³⁶	8	No mention of psychosis history, 0 psychotic MDEs	No mention of comorbidity	No mention of antipsychotics, 0 on AP? Not sure

working memory theory is used to interpret the cognitive impairment in euthymic bipolar disorder, and deficits are associated with the condition.¹⁹ Working memory is postulated to be composed of a central executive control system that monitors 2 independent subsystems: a visuospatial sketchpad for spatial processing and a phonological loop for nonspatial, mainly verbal information.^{20,21} See Table 1 for evidence of how visual spatial working memory are affected in bipolar disorders.

Quality Assessment

Research reports were assessed by the authors using 7 criteria: selection bias, design, confounders, blinding, data collection, methods, and withdrawals and dropouts. The "Quality Assessment Tool for Quantitative Studies"³⁷ developed by the Effective Public Health Practice Project (EPHPP) is a tool for knowledge synthesis. This instrument, along with a user manual, provides a standardized means to assess study quality and develop recommendations for study findings. The quality appraisal tool was developed by the Effective Public Health Practice Project (EPHPP) as a discrete step within the systematic review

process. Validity and reliability properties meet accepted standards. The scoring is divided into 3 categories, strong=3, moderate=2, weak=1 and a sum total of each for the overall score. The authors of this review contacted all authors of the studies, who were given an opportunity to agree or disagree with the rating. If discrepancies were found in the initial study rating, scores were updated based on evidence provided by authors, all of whom agreed to their individual ratings in Table 2.

Results

The systematic search yielded 59 articles, 17 of which are relevant for and included in this review. Table 3 summarizes the findings of all of the studies included in this review. Results will be described here based on sample size, cognitive task used, main findings, and limitations. First, we give a more detailed description of all of the cognitive tasks and domains used in each of these studies (Table 2), and then we present an in depth review of the most relevant domains (Table 3).

TABLE 3. Neuropsychological classifications of tests used in each study

Author	Verbal memory	Visual memory	Planning/set shifting	Attention	Working memory	Processing speed	Verbal fluency	Premorbid IQ	Reasoning & problem solving	Executive function
Bourne ²²	Rey Auditory Verbal Learning Test (Rey, 1941)									
Sparding ²⁴	The Claeson Dahl Verbal Learning and Retention Test	The Rey Complex Figure Test (ROCFT)	Delis Kaplan Executive Function (D-KEFS)	Continuous performance test II (CPT-II)	WAIS-III	WAIS-III	WAIS-III	N/A	WAIS-II (Block design/matrix reasoning)	Delis Kaplan Executive Function (D-KEFS)
Lin ²⁵	Digit span backwards of WAIS-RC	Immediate visual reproduction subtest of WMS-RC	Wisconsin Card Sorting Test	Digit span forward subtest of WAIS-RC	WAIS-RC Digit Symbol coding subtest	Trail Making Test A	Animal naming test		Tower of Hanoi	Trail Making Test B Wisconsin Card Sorting Test
Aminoff <i>et al</i> ¹	California Verbal Learning Test (CVLT-II)				Bergen n-back test (2-back)	Digit Symbol Test [Wechsler Adult Intelligence Scale, Third Revision (WAIS-III)]	Verbal Fluency Test [Delis–Kaplan Executive Function Scale (D-KEFS)]	National Adult Reading Test (NART)		Color-Word Interference
Kessler ²³	Hopkins Verbal Learning Test Revised (HVL-R)	Brief Visuospatial Memory Test Revised (BVMT-R)		Continuous Performance Test-Identical Pairs (CPT-IP); Trail Making Test A	Wechsler Memory Scale: third edition (WMS-III):	Symbol Coding	Category Fluency; Animal naming test	Wechsler Abbreviated Scale of Intelligence (WASI); the NART		Tower of London
Palsson ³⁵	Claeson Dahl Verbal Memory	Rey Complex Figure Test	ROCFT	ROCFT	D-KEFS		D-KEFS			D-KEFS; Tower Test; Trail Making B
Ha <i>et al</i> ²⁶	Korean-California Verbal Learning Test (K-CVLT)	Rey Complex Figure Test	ROCFT	ROCFT				Vocabulary and Block Design subtests (WAIS-R)		ROCF organization score
Simonsen <i>et al</i> ³³	CVLT-II; WMS-III Logical Memory				Working Memory—M Arith WM-MA; Digit Span Test —backward (WAIS-III)	WAIS-III Digit Symbol; Digits;	D-KEFS verbal fluency	NART-IQ;		D-KEFS Color word interference for interference
Hsiao <i>et al</i> ³⁴	Verbal Paired Associates (VPA I and II)	WMS-III (Logical Memory I and II visual memory)			WMS-III (Logical Memory I and II)	WAIS-III Digit Symbol; Digits; TMT-A				TMT-B BDI < BDII
Dittmann <i>et al</i> ³¹	RBANS	RBANS		RBANS	WAIS-III Letter–Number Sequencing	TMT-A	RBANS	HAWIE R		TMT-B
Savitz <i>et al</i> ³²	RAVLT; Digits back	ROCFT;		Digits forward		WAIS III Digits	COWAT	SA-WAIS General Knowledge (interference)		WCST; Stroop (interference)
Bruno <i>et al</i> ²⁸	Doors and People Test	ROCFT; SWM			SWM			IQ NART; IQ WAIS-R;		IDED of CANTAB
					N Back Test; A not B RT	WAIS-III Digit Symbol	FAS	IQ NART; IQ WAIS-R;		TMT-B

Harkavy-Friedman <i>et al</i> ²⁹	Buschke Selective Reminding Test,	Benton Visual Retention Task (BVRT)	Continued Performance Test; Stroop				
Summers <i>et al</i> ³⁰	Recognition Memory Test; PALT; Doors and People Test	ROCFT; Recognition Memory Test,	TMT-A;		COWAT	IQ NART; IQ WAIS	TMT-B ; IDED Set-Shift; MCST (Modified Wisconsin); SCWT,
Torrent <i>et al</i> ⁹ Smith ³⁶	CVLT CVLT		TMT-A;	WAIS Digits	FAS; Animal Naming;	WAIS Voc NART; Block Design WAIS	TMT-B; WCST, SCWT Brixton Spatial Anticipation Test; TMT B; Stroop Color Word Test
Martinez-Aran <i>et al</i> ²⁷	CVLT + Animal Naming + Logical Memory	WMS-R Visual Reproduction	TMT-A	WAIS digits	FAS	WAIS Voc	TMT-B; WCST; SCWT

Task/Domain	Difference	State
BP-IVBP-II		
Trail Making Test–Part B		
<i>Lin (2015)</i>	BPI<BP-II*	depressed
<i>Hsiao (2009)</i>	BPI<BP-II	interepisode
<i>Torrent (2008)</i>	BP-II<BPI	euthymic
<i>Martinez- Aran (2004)</i>	BPI=BP-II	D+M+E*
<i>Dittman (2008)</i>	BPI=BP-II	euthymic
<i>Palsson (2013)</i>	BPI=BP-II	euthymic
<i>Harkavy- Friedman et al (2006)</i>	BPI=BP-II	depressed
D-KEFS		
<i>Sparding (2015)</i>	BPI=BP-II	euthymic
<i>Aminoff (2015)</i>	BPI=BP-II	57% of sample depressed
Tower of London		
<i>Kessler (2013)</i>	BPI=BP-II	E&D
Rey–Osterrieth complex figure test (ROCF) organization score		
<i>TH Ha (2012)</i>	BPI=BP-II	euthymic**
CANTAB IED		
<i>Summers (2006)</i>	BP-II<BPI	euthymic
MATRICS		
<i>Kessler (2013)</i>	BPI=BP-II	Both E&D

* where < means lower scores on cognitive tests.
**absence of severe mood episode.

FIGURE 2. BP-I vs BP-II executive function.

Next, we present accounts of each cognitive domain in the Figures 2–7 to give a more in depth review and clear answer as to whether (i) neurocognitive dysfunction in BP-II is similar to BP-I in each cognitive domain and (ii) whether these deficits exist in subsyndromal disorders SBP. Due to the limited amount of studies and to provide a more transparent account of the neuropsychological profile of (SBP), we have divided the results as follows: (i) comparison of neuropsychological functioning between BP-I and BP-II and (ii) neuropsychological functioning in SBP.

Global intellectual function

Most of the studies (11 of 17) included an IQ measure in their analysis, all of which failed to detect significant differences in the IQ of BD II patients compared with BD I patients, and between subthreshold disorders and

both major depressive disorders and healthy control subjects.

Executive function

Most of the articles (13 of 17) looked at executive function, all of which directly compared EF between BP-I and BP-II. All patient groups scored lower on tests compared to healthy controls (see Figure 2). Nine of these 13 studies showed no difference in cognitive dysfunction between groups, with Sparding et al²⁴ concluding that EF most reliably detected cognitive impairments in the patient group using the Trail Making Test B as their cognitive task. Ha et al also found no difference between groups and concluded that executive dysfunctions exert additional influence on memory impairment. Both Sparding et al's and Ha et al's samples were euthymic, along with those of 3 other studies, ie, 5

Task/Domain	Difference	State
Continuous performance Test (CPT-II)		
<i>Sparding (2015)</i>	BPI=BPII	euthymic
<i>Kessler (2013)</i>	BPI=BPII	E&D
<i>Harkavy-Friedman et al.(2006)</i>	BPI=BPII	depressed
ROCFT		
<i>Palsson (2013)</i>	BPI=BPII	euthymic
<i>TH Ha (2012)</i>	BPI=BPII	euthymic**
RBANS		
<i>Dittmann (2008)</i>	BPI=BPII	euthymic
<i>Hsiao (2009)</i>	BPI<BPII*	interepisode
WAIS Digits forward		
<i>Lin (2015)</i>	BPI<BPII	depressed
<i>Savitz</i>	BPI<BPII	euthymic
<i>Simonsen (2011)</i>	BPI=BPII < HC	all states
TMT-A		
<i>Martinez-Aran (2004)</i>	BPI=BPII	30 D, 34 M, 44 E

*where < means lower scores on cognitive tests.

**absence of severe mood episode.

FIGURE 3. Attention in BP-I v. BP-II.

euthymic studies that found no difference in total. There were 4 studies that showed a different profile between BP-I and BP-II, 1 in a depressed sample, 1 euthymic, and the other 2 had a mixed sample of both euthymic and depressed patients.

Attention

Many of the studies (11 of 17) looked at attention, all of which directly compared scores on attention between BP-I and BP-II. Most studies used the Continuous Performance Test (CPT-II) as their cognitive measure to assess attention. See Figure 3.

Two studies, 1 in an inter-episode sample and 1 in an “all states” sample, found BP-I to be more cognitively impaired than BP-II. One other study found BP-I to be more cognitively impaired than BP-II, this time in a euthymic sample. Eight studies found no difference

between BP-I and BP-II, 3 of which were in euthymic samples.

Verbal learning and memory

Almost all studies (15 of 17) looked at learning and verbal memory, all of which directly compared neuropsychological performance between BP-I and BP-II (see Figure 4). Six studies in total found that BP-I performed significantly worse than BP-II in measures of verbal memory. Four of these studies were in a euthymic sample, 1 in a depressed sample, and 1 in an “all states” sample.

Seven studies found no difference between BP-I and BP-II in verbal memory, 4 of which were euthymic samples, 2 were both euthymic and depressed samples, and the other 1 was a depressed sample. Two studies found that BP-II had more verbal memory impairment than BP-I; however, the small sample size of BP-II in 1 of

Task/Domain	Difference	State
BP-I v BP-II		
Rey Auditory Verbal Learning Task		
<i>Bourne (2015)</i>	BPI<BP-II*	euthymic
<i>Savitz (2008)</i>	BPI<BP-II	euthymic
California Verbal Learning Test (CVLT)		
<i>Martinez (2004)</i>	BPI<BP-II	30 D, 34 M, 44 E
<i>Torrent (2006)</i>	BPI<BP-II	euthymic
<i>Aminoff (2013)</i>	BPI=BP-II	57% of sample were depressed
<i>TH Ha (2012)</i>	BPI=BP-II	euthymic*
Hopkins Verbal Learning Task Revised		
<i>Kessler (2013)</i>	BPI=BP-II	E&D
Claeson Dahl Verbal Learning		
<i>Palsson (2013)</i>	BPI=BP-II	Euthymic
<i>Sparding (2015)</i>	BPI=BP-II	Euthymic
RBANS		
<i>Dittman (2008)</i>	BPI=BP-II	euthymic
Test-Second Edition (CVLT-II)		
<i>Simonsen (2011)</i>	BPI<BP-II	euthymic**
Digits WAIS		
<i>Lin (2015)</i>	BPI<BP-II	depressed
Bushke Selective Recall Test		
<i>Harkavy-Friedman</i>	BPI<BP-I	depressed
Recognition Memory Test		
<i>Summers (2006)</i>	BPI<BP-I	E&D
<i>Bruno (2006)</i>	BPI<BP-I	euthymic

*where < means lower scores on cognitive tests.
**absence of severe mood episode.

FIGURE 4. Verbal memory.

these studies should be taken into account, as it could have led to type-II errors.

Visual spatial working memory

Twelve out of 17 studies looked at visual spatial working memory (see Figure 5). Seven studies in total showed no difference, 5 were in euthymic samples, 1 in a depressed sample, and the other in an “all states” sample. Two studies found that BP-II patients were more cognitively impaired than BP-I. Two showed a difference between the 2 patient groups, and 1 found BP-I and BP-II to have no impairment, ie, similar performance to healthy controls.

Working memory

Ten out of 17 studies looked at working memory, all of which directly compared BP-I and BP-II. All studies showed patient groups to be more impaired than healthy controls. Seven studies showed no difference between BPI and BP-II, 4 of which were euthymic samples (see Figure 6).

Neuropsychological function in subthreshold bipolar disorders

Two out of the 17 studies included in this review investigated neuropsychological functioning in sub-threshold bipolar disorders, comprising the only available literature on this subject, to the authors’

Task/Domain	Difference	State
Rey Osterrieth Complex Figure Test		
<i>Savitz (2008)</i>	BPII<unaffected r	euthymic
<i>Sparding (2015)</i>	BPI=BPII	Euthymic
<i>Palsson (2013)</i>	BPI=BPII	euthymic
<i>TH Ha (2012)</i>	BPI=BPII	euthymic**
BVRT		
<i>Harkavy Friedman (2006)</i>	BPI=BPII	depressed
RBANS		
<i>Dittmann (2008)</i>	BPI=BPII	euthymic
Doors and People Test		
<i>Bruno (2006)</i>	BPII<BPI*	euthymic
<i>Summers (2006)</i>	BPII<BPI	9 D, rest euthymic
WMS-III		
<i>Hsiao (2009)</i>	BPI=BPII=HC	interepisode
<i>Simonsen (2011)</i>	BPI=BPII < HC	all states
WMS-R		
<i>Martinez-Aran (2004)</i>	BPI=BPII	30 D, 34 M, 44, E
HAWIE-R		
<i>Dittman (2008)</i>	BPII<HC=BPI	euthymic

*where < means lower scores on cognitive tests.
**absence of severe mood episode.

FIGURE 5. Visual spatial / working memory.

knowledge. Both studies investigated the 3 cognitive domains of executive function, verbal memory, and attention and used a strict unipolar MDD sample for comparison, while only 1 also included a BP-II sample (see Figure 6). One study, in a depressed sample, showed that individuals who met criteria for a bipolar spectrum disorder were more cognitively impaired than those with strict unipolar MDD, while they shared a similar cognitive profile to BP-II. The other study, in a euthymic sample, showed that individuals who met criteria for a subthreshold bipolar disorder performed cognitively better than strict unipolar MDD. This study did not include a BP-II comparison.

Discussion

This review set out to (a) provide an update on neuropsychological functioning in BP-I and BP-II, (b)

review all literature pertaining to neuropsychological functioning in SBP, and (c) discuss the plausibility of a dimensional approach to understanding bipolar disorders. Regarding (a), we found that when accounting for the cognitive domains of executive function, verbal memory, attention, working memory, and visual spatial working memory, more studies than not show a similar cognitive profile between BP-I and BP-II. Two additional studies found that BP-II performed worse than BP-I in visual spatial working memory. Regarding executive function, 9 out of 13 studies found no difference between these patient groups, most of which (5 of 9) consisted of euthymic samples with large sample sizes (64 BP-I vs 44 BP-II, 65 BP-I vs 38 BP-II, 67 BP-I vs 43 BP-II, 37 BP-I vs 46 BP-II, 127 BP-I vs 72 BP-II), and the majority of which (4 of 9) used Trail Making Test B (TMT-B) as their measure for executive function. TMT-B has been validated to test an individual's cognitive flexibility, which some researchers

Task/Domain	Difference	State
BP-I v BP-II		
WAIS-III		
<i>Sparding (2015)</i>	BPI=BPII	euthymic
<i>Dittmann (2008)</i>	BPI=BPII	euthymic
<i>Hsiao (2009)</i>	BPI=BPII	interepisode
<i>Simonsen (2008)</i>	BPI=BPII	all states
N-back task		
<i>Aminoff (2013)</i>	BPI=BPII	57% of sample were depressed
<i>Harkavy Friedman (2006)</i>	BPI=BPII	depressed
WMS-III		
<i>Kessler (2013)</i>	BPI=BPII	E&D
D-KEFS		
<i>Palsson (2013)</i>	BPI=BPII	Euthymic
SWM		
<i>Bruno (2006)</i>	BPI=BPII	euthymic
WAIS-RC		
<i>Lin (2015)</i>	BPI=BPII*	depressed

*where < means lower scores on cognitive tests.

FIGURE 6. Working memory.

understand as executive function. Clinicians should be aware of the severity of cognitive impairment in BP-II, particularly in the areas of executive function, verbal memory, attention, and visual spatial working memory. Important potential confounding factors for why some studies show BP-I to have a more severe cognitive profile than BP-II will be highlighted below in the limitations section.

Considering (b), SBP patients share a similar cognitive profile to BP-II and have a different cognitive profile to strict unipolar MDD, ie, in the areas of executive function, attention, and verbal memory. Although the sample size was generous in both studies, findings need to be interpreted with caution, mainly due to this conclusion being based on a mere 2 studies but also due to other important reasons which are highlighted below in the limitations section.

Last, we come to (c), and utilizing our findings from both (a) and (b), we can see how neuropsychological alterations may appear similar across subtypes of bipolar disorders, revealing that this condition may be better understood as a spectrum. With this evidence, therefore, we can conclude that neuropsychological functioning, particularly in the areas of executive function, verbal learning, and attention, may represent an endophenotype for 1 current categorical classification,

ie, bipolar disorder and related subtypes. These findings are directly applicable to other mental illnesses, and dimensional approaches should be used to better our understanding. We have seen how cognitive dysfunction seems to play an important role across the bipolar spectrum, and scientists are urged to utilize such dimensional approaches when investigating neurobiological underpinnings. How such alterations compare across current DSM-5 classifications of mental illness (eg, major depression, bipolar disorder) would be an interesting undertaking. We have not seen much success with genetics and imaging studies so far; however, research on cognition and neuropsychological testing could pave the way forward. The field is in its infancy, and if we are to move in the right direction, we need to refine our approach to elucidate important clinical factors such as cognitive function and related processes. Investigating the neuroscientific underpinnings of cognition is of equal importance, and below we discuss this topic further.

Limitations

The findings of studies included in this review have many limitations.

Task/Domain	Difference	State
Executive Function		
Trail Making Test–Part B (TMT-B)		
<i>Lin (2015)</i>	BP-II=SSBD>MDD	depressed
<i>Smith (2006)</i>	SSBD>MDD&HC	euthymic
Verbal Learning		
Digit span backwards of WAIS-RC		
<i>Lin (2015)</i>	BP-II=SSBD>MDD	depressed
California Verbal Learning Test (CVLT)		
<i>Smith (2006)</i>	SSBD<MDD&HC*	euthymic
Attention		
Digit Span Forward subtest of the WAIS-RC		
<i>Lin (2015)</i>	BP-II=SSBD<MDD	depressed
The Brixton Spatial Anticipation test		
<i>Smith (2006)</i>	SSBD>MDD&HC	euthymic

*where < means lower scores on cognitive tests.

FIGURE 7. SBP vs MDD vs BP-II.

BP-I vs BP-II limitations

Medication

An important limitation to be considered with regard to the studies included in this review is the use of antipsychotics not controlled for in these studies. While some studies suggest BP-II is similar to BP-I, many have found different cognitive profiles between the 2 groups, and 1 important reason for this may be due to the differential use of medication within samples. For example, Palsson et al in Sweden found that bipolar type I and type II were cognitively impaired compared to healthy controls, and there were no statistically significant differences between the 2 subtypes (I and II). The strongest predictor of cognitive impairment within the patient group was current antipsychotic treatment. Palsson et al suggested that the type and degree of cognitive dysfunction is similar in bipolar I and II patients; they add that “treatment with antipsychotics—but not a history of psychosis was associated with more severe cognitive impairment” (p. 1).³⁵ Given that patients with bipolar I disorder are more likely to be on antipsychotic drugs, this might explain why some previous studies have found that patients with type I bipolar disorder are more cognitively impaired than those with type II.³⁵ Furthermore, Kessler et al found that a high proportion of patients

with therapy-resistant BP-I or BP-II depression exhibited global neurocognitive impairments with clinically significant severity.²³ The cognitive impairments were more common in BP-I compared to BP-II patients, particularly processing speed. However, there were other important differences between the samples including the BP-I group having had a shorter duration of education and more BP-I patients taking anti-psychotics. Many patients with this disorder take several psychotropic medications at varying doses, and it is unknown what the cognitive effects of combined therapy might be, particularly over time.

Neuropsychological tests

A further limitation of the studies in this review is that each utilizes a wide variety of different measures, each with its own limitations, and it is clear that a consensus should be made on the tasks that most likely test the most important cognitive domains. This review suggests TMT-B for executive function, CVLT for verbal learning and memory, N-back working memory tool for visual working memory, and the Continuous Performance Test (CP-II) or Digit Symbol Substitution Test (DSST) for attention to be the most suitable.

Comorbidities

Furthermore, an important limitation that needs to be considered is that comorbid conditions have not been discussed to much extent in many of the studies included in this review. Comorbidity (psychiatric and medical) in bipolar disorders is generally very high, and this is clearly of clinical importance, but even more so if we are to begin to attempt to understand the etiology of cognitive impairments. Comorbidity is especially high in BP-II and SSBD, particularly in terms of anxiety disorders and personality disorders, and it has been questioned whether multiple individual diagnoses (constructs largely derived from clinical presentation as categorized in the DSM-5) are the most efficient way of moving forward in our attempt to understand frequently co-occurring symptoms. Severity, for example, is not considered in this way.

SBP limitations

Patient selection

One important limitation is the criteria used in each study's samples. For example, both authors of the 2 SBP studies in this review use the term spectrum disorders SBP²⁵ and BSD³⁶ with inclusion criteria based on the definition by Ghaemi et al and Akiskal and Pinto³⁸, respectively. Therefore, it is difficult to ascertain from both authors' definitions and the details presented whether these patients would meet criteria for BP-NOS or SBP-ME (mixed episodes), and indeed they could also be cyclothymic. For example, Lin et al categorically re-assigned those with MDD into 81 SBP (36 bipolar II 1/2, 9 bipolar III, and 36 bipolar IV using the Akiskal and Pinto criteria; please see Appendix 2 for reference to this criteria). Smith et al used definitions according to BSD diagnostic criteria from Ghaemi et al (see Appendices). Despite the availability of more defined categories, such as in the DSM-5, there is a paucity of studies that use such criteria, and future studies would benefit from such a refined approach.

Mood state

A further limitation is that although SBP patients were shown to be different from strict unipolar MDD, the results of the 2 available studies to date are contradictory, which may be due to the different SBP criteria used or it may be due to the different mood states recruited within groups. For example, Smith et al found euthymic patients with BSD were significantly better than MDD patients and controls on tests of executive function and verbal memory, whereas Lin et al found

the opposite in a sample of depressed patients. On the other hand, Lin et al's data suggest that patients with BSD perform significantly worse than strict unipolar MDD. Further research might benefit from using the strict DSM-5 criteria along with a strict euthymic sample.

Conclusions

It appears pertinent that bipolar disorder type II (BP-II) has cognitive impairments that are just as severe as they are in bipolar disorder type I (BP-I), and in some cases more so, specifically in the areas of executive function and visual spatial working memory. Executive function is a construct that is most vulnerable to the effects of stress exposure, and this might be even more pronounced with both of these conditions. Reasons for this are unknown. However, it is interesting that Smith found in his sample that patients with subthreshold disorders performed significantly better than both MDD and healthy controls. What happens to individuals with subthreshold bipolar disorders over time?

The possibility of a link between bipolar disorder and positive attributes such as intelligence and creativity have been discussed since antiquity.³⁹ Whether, and how, IQ may relate to neuropsychological dysfunction is unclear; however, Smith et al³⁹ found that childhood IQ was associated with bipolar disorder, and that intellectual function may be an endophenotype biomarker for bipolar disorders. If SBP were found to be an early onset BP-II or BP-I disorder, it might be likely that intelligence is indeed, as Smith and colleagues suggest, a predictor and endophenotype biomarker for bipolar disorders,³⁹ and that such factors may lead to more severe alterations in mood, activity, and biological rhythms.

Implications

Unrecognized bipolarity is thought to be a significant factor contributing to treatment resistance in depression,⁴⁰ and is therefore of great potential significance as a possible predictor of treatment response. A traditional categorical approach to major depressive disorders in the context of major depressive disorder (MDD) and subthreshold bipolar disorders (SBP), in particular BP-NOS, may be limiting for research purposes, and a dimensional approach to neuropsychiatric illnesses such as the Research Domain Criteria (RDoC) could be considered as a model to work toward. RDoC is an attempt to create a new kind of taxonomy for mental disorders by bringing the power of modern research approaches in genetics, neuroscience, and

behavioral science to the problem of mental illness.⁴¹ A stratified model such as RDoC may lead to better understanding of these underlying conditions so that more appropriate treatments can be implemented for patients.

Neuropsychological functioning represents one of the key RDoC constructs that crosses DSM-5 boundaries and may substantially enhance our understanding of the pathophysiology of diverse illnesses, such as the heterogeneity of MDD. While RDoC is still in its infancy, nevertheless, future research should work toward an RDoC approach. A pragmatic precision medicine model currently being explored is “the development of a neural circuit taxonomy suited to clinical actions to address the gap between brain imaging advances and practice” (p. 2).⁴² William’s approach provides the foundation for a “taxonomy of putative types of dysfunction, which cuts across traditional diagnostic boundaries for depression and anxiety and includes instead distinct types of neural circuit dysfunction that together reflect the heterogeneity of depression and anxiety.”⁴² This taxonomy provides a foundation for building research evidence to help guide clinical practice. Cognitive remediation strategies are one such example. Future research should investigate cognitive functions and neural circuits across major depressive disorders by administering short neuropsychological assessments and carry out MRI studies to gain a further understanding of the underlying mechanisms of cognitive dysfunction.

Protocol for future studies

Regarding neuropsychological tests that should be used, this review suggests TMT-B for executive function, CVLT for verbal learning and memory, N-back working memory tool for visual working memory, and Continuous Performance Task for attention. The THINC battery⁴³ is a digitized cognitive test application designed to assess cognitive function in MDD and administers the following cognitive test components: Digit Symbol Substitution Test (DSST), Trail Making Test B (TMT-B), Choice Reaction Time (CRT) One-back working memory tool, and Perceived Deficits Questionnaire-5 Depression (PDQ-5-D). This tool can be administered in 20 minutes, and although it does not involve a verbal learning task, it may be a short and concise method of assessing and distinguishing bipolar disorders from MDD. Strict euthymic criteria should be used in all patient groups, to rule out the effect of sub-syndromal depressive symptoms. Including euthymic samples has also been recommended by the International Society for Bipolar Disorders Targeting Cognition Task Force.⁴⁴ Other key methodological

challenges they suggest are lack of consensus on how to screen for entry into cognitive treatment trials, define cognitive impairment, track efficacy, assess functional implications, and manage mood symptoms and concomitant medication. The authors’ recommendations are to “(a) enrich trials with objectively measured cognitively impaired patients; (b) generally select a broad cognitive composite score as the primary outcome and a functional measure as a key secondary outcome; and (c) include remitted or partly remitted patients” (p. 1).⁴⁴ Furthermore, there are no studies in this review that have used the most recent DSM-5 criteria for SBP (ie, BP-NOS), and future studies should address this.

Strengths and weaknesses

To our knowledge, this is the first review to investigate systematically the literature on the relationship between neuropsychological dysfunction and subthreshold bipolar disorders. One main strength of this review is the culmination of a quality assessment of each study included, the results of which indicate that there are a significant number of potential confounders not controlled for, such as use of antipsychotics particularly in BP-I, history of psychosis, and comorbidities. The review discussed the implications of these confounders in more detail, suggests that a consensus should be agreed upon as to how studies should be carried out, and includes a recommended protocol for future studies. A meta-analysis was not possible with the available data from current studies, something which would be of real value in the future if methodology of studies will allow. The conclusions drawn from the SBP studies are based on 2 articles, and more research in the area is necessary, particularly studies that utilize a more refined methodology approach, as outlined above. Last, we only used English language articles. (Tables 4–9)

Supplementary material

To view supplementary material for this article, please visit <https://doi.org/10.1017/S1092852918001463>

REFERENCES:

1. Aminoff SR, Hellvin T, Lagerberg TV, Berg AO, Andreassen OA, Melle I. Neurocognitive features in subgroups of bipolar disorder. *Bipolar Disord.* 2013; **15**(3): 272–283.
2. Doruk A, Yazihan NT, Balıkcı A, Erdem M, Bolu A, Ates MA. Cognitive functions in bipolar manic, depressed and remission episodes. *Klinik Psikofarmakol Bulteni.* 2014; **24**(1): 59–68.

3. Kahani M, Talaei A, Mokhber N, Fayyazi Bordbar M, Dolatshahi M. Executive functions in patients with bipolar I disorder in recovery phase: a case-control study. *J Mazandaran Univ Med Sci*. 2013; **23** (101): 96–103.
4. Radwan DN, Okasha T, Elmisiery M, Sadek H, Khalifa A, Abdelaziz K. Cognitive impairment in Egyptian euthymic patients with bipolar I disorder compared with controls. *Middle East Current Psychiatry, Ain Shams University*. 2013; **20**(4): 197–204.
5. Santos JL, Aparicio A, Bagnay A, et al. A five-year follow-up study of neurocognitive functioning in bipolar disorder. *Bipolar Disord*. 2014; **16**(7): 722–731.
6. Andersson S, Barder HE, Hellvin T, Lovdahl H, Malt UF. Neuropsychological and electrophysiological indices of neurocognitive dysfunction in bipolar II disorder. *Bipolar Disord*. 2008; **10**(8): 888–899.
7. Bora E, Yucel M, Pantelis C, Berk M. Meta-analytic review of neurocognition in bipolar II disorder. *Acta Psychiatr Scand*. 2011; **123**(3): 165–174.
8. Sole B, Bonnin CM, Torrent C, et al. Neurocognitive impairment across the bipolar spectrum. *CNS Neurosci Ther*. 2012; **18**(3): 194–200.
9. Torrent C, Martínez-Aran A, Daban C, et al. Cognitive impairment in bipolar II disorder. *Br J Psychiatry*. 2006; **189**(3): 254–259.
10. Angst J, Azorin JM, Bowden CL, et al. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. *Arch Gen Psychiatry*. 2011; **68**(8): 791–798.
11. Ghaemi SN, Sachs GS, Chiou AM, Pandurangi AK, Goodwin K. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? *J Affect Disord*. 1999; **52**(1–3): 135–144.
12. Goeldner C, Ballard TM, Knoflach F, Wichmann J, Gatti S, Umbrecht D. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. *Neuropharmacology*. 2013; **64**:337–346.
13. Iverson GL, Brooks BL, Langenecker SA, Young AH. Identifying a cognitive impairment subgroup in adults with mood disorders. *J Affect Disord*. 2011; **132**(3): 360–367.
14. Bora E, Harrison BJ, Yucel M, Pantelis C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. *Psychol Med*. 2013; **43**(10): 2017–2026.
15. Robinson L, Thompson J, Gallagher P, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. *J Affect Disord*. 2006; **93**(1–3): 105–115.
16. Arnsten AFT. Stress signalling pathways that impair prefrontal cortex structure and function. *Nat Rev Neurosci*. 2009; **10**(6): 410–422.
17. Siddiqui SV, Chatterjee U, Kumar D, Siddiqui A, Goyal N. Neuropsychology of prefrontal cortex. *Indian J Psychiatry*. 2008; **50** (3): 202–208.
18. Addis DR, Hach S, Tippett LJ. Do strategic processes contribute to the specificity of future simulation in depression? *Br J Clin Psychol*. 2016; **55**(2): 167–186.
19. Thompson JM, Hamilton CJ, Gray JM, et al. Executive and visuospatial sketchpad resources in euthymic bipolar disorder: implications for visuospatial working memory architecture. *Memory*. 2006; **14**(4): 437–451.
20. Baddeley A. Working memory. *Science*. 1992; **255**(5044): 556–559.
21. Baddeley A, Logie R, Bressi S, Della Sala S, Spinnler H. Dementia and working memory. *Q J Exp Psychol A*. 1986; **38**(4): 603–618.
22. Bourne C, Bilderbeck A, Drennan R, et al. Verbal learning impairment in euthymic bipolar disorder: BDI v BDII. *J Affect Disord* 2015; **182**: 95–100.
23. Kessler U, Schoeyen HK, Andreassen OA, et al. Neurocognitive profiles in treatment-resistant bipolar I and bipolar II disorder depression. *BMC Psychiatry*. 2013; **13**:105.
24. Sparding T, Silander K, Pålsson E, et al. Cognitive functioning in clinically stable patients with bipolar disorder I and II. *PloS One* 2015; **10**(1): e0115562–e62.
25. Lin K, Xu G, Lu W, et al. Neuropsychological performance of patients with soft bipolar spectrum disorders. *Bipolar Disord*. 2015; **17**(2): 194–204.
26. Ha TH, Kim JS, Chang JS, et al. Verbal and Visual Memory Impairments in Bipolar I and II Disorder. *Psychiatry investigation* 2012; **9**(4): 339–346.
27. Martínez-Aran A, Vieta E, Reinares M, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. *Am J Psychiatry* 2004; **161**(2): 262–270.
28. Bruno SD, Papadopoulou K, Cercignani M, Cipolotti L & Ron MA. Structural brain correlates of IQ changes in bipolar disorder. *Psychol Med* 2006; **36**(5): 609–618.
29. Harkavy-Friedman JM, Keilp JG, Grunebaum MF, et al. Are BPI and BPII suicide attempters distinct neuropsychologically? *J Affect Disord* 2006; **94**(1–3): 255–259.
30. Summers M, Papadopoulou K, Bruno S, Cipolotti L, Ron MA. Bipolar I and bipolar II disorder: cognition and emotion processing. *Psychol Med* 2006; **36**(12): 1799–1809.
31. Dittmann S, Hennig-Fast K, Gerber S, et al. Cognitive functioning in euthymic bipolar I and bipolar II patients. *Bipolar disorders* 2008; **10**(8): 877–887.
32. Savitz JB, van der Merwe L, Stein DJ, Solms M & Ramesar RS. Neuropsychological task performance in bipolar spectrum illness: genetics, alcohol abuse, medication and childhood trauma. *Bipolar disorders* 2008; **10**(4): 479–494.
33. Simonsen C, Sundet K, Vaskinn A, et al. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. *Schizophrenia Bulletin* 2011; **37**(1): 73–83.
34. Hsiao YL, Wu YS, Wu JY, et al. Neuropsychological functions in patients with bipolar I and bipolar II disorder. *Bipolar disorders* 2009; **11**(5): 547–554.
35. Pålsson E, Figueras C, Johansson AG, et al. Neurocognitive function in bipolar disorder: a comparison between bipolar I and II disorder and matched controls. *BMC Psychiatry*. 2013; **13**:165.
36. Smith DJ, Muir WJ, Blackwood DH. Neurocognitive impairment in euthymic young adults with bipolar spectrum disorder and recurrent major depressive disorder. *Bipolar Disord*. 2006; **8**(1): 40–46.
37. Thomas BH, Ciliska D, Dobbins M, Micucci S. A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. *Worldviews Evid Based Nurs*. 2004; **1**(3): 176–184.
38. Akiskal HS & Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. *The Psychiatric clinics of North America* 1999; **22**(3): 517–534.
39. Smith DJ, Anderson J, Zammit S, Meyer TD, Pell JP, Mackay D. Childhood IQ and risk of bipolar disorder in adulthood: prospective birth cohort study. *BJPsych Open*. 2015; **1**(1): 74–80.
40. Correa R, Akiskal H, Gilmer W, Nierenberg AA, Trivedi M, Zisook S. Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? *J Affect Disord*. 2010; **127** (1–3): 10–18.
41. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. *BMC Med*. 2013; **11**(1): 126.
42. Williams LM. Precision psychiatry: a neural circuit taxonomy for depression and anxiety. *Lancet Psychiatry*. 2016; **3**(5): 472–480.

43. McIntyre RS, Best MW, Bowie CR, *et al.* The THINK-Integrated Tool (THINC-it) screening assessment for cognitive dysfunction: validation in patients with major depressive disorder. *J Clin Psychiatry*. 2017; **78**(7): 873–881.
44. Miskowiak KW, Burdick KE, Martinez-Aran A, *et al.* Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force. *Bipolar Disord*. 2017; **19**(8): 614–626.